Digital biomarker to enhance precision, reduce patient burden and boost efficiency of global Phase 2 trial of NEU-411 in early Parkinson’s disease SOUTH SAN FRANCISCO, Calif.--(BUSINESS ...
NEW YORK, NY AND TUCSON, AZ (September 9, 2024) — The U.S. Food and Drug Administration (FDA) encouraged scientists and drug developers to use the alpha-synuclein seed amplification assay (αSyn-SAA) ...
Hosted on MSN
Digital biomarkers market poised for $17.73b expansion by 2031 amidst remote monitoring surge
Clinical trials expand use of real-world data capture through digital monitoring tools. The digital biomarkers market is projected to grow to $17.73b by 2031, with a compound annual growth rate of ...
The rise of AI has powered a wave of interest in digital innovation within pharma. But to have a lasting impact, AI — like any innovation in digital health — must be able to deliver value by being ...
While artificial intelligence (AI) has shown promising potential, much of its use has remained theoretical or retrospective. Turning its potential into real-world health care outcomes, researchers at ...
WASHINGTON, D.C., March 19, 2026 (GLOBE NEWSWIRE) -- NeuroRPM, a digital health company focused on Parkinson’s disease monitoring, today announced that its FDA-cleared wearable platform will be used ...
Validated biomarkers will help physicians identify patient subgroups that will benefit most from specific treatment ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Neuron23® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological ...
Digital biomarker to enhance precision, reduce patient burden and boost efficiency of global Phase 2 trial of NEU-411 in early Parkinson's disease SOUTH SAN FRANCISCO, Calif.--(BUSINESS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results